© 2014 PrimeVax Immuno-Oncology


Investor Relations

PrimeVax is a clinical stage biotechnology company with our first indication for PD-1 failed melanoma. We have just opened our first IND with FDA. We are currently mobilizing our clinical trial site. A non-confidential slide deck may be provided for potential partnership contacts. 


Business development point of contact:


Tony Chen

CEO, PrimeVax